Tag: OCRA Research
OCRA-Funded Study Reveals Promising Therapeutic Option for Boosting Ovarian Cancer Immune Response
Targeting a specific oncogene associated with the most common type of ovarian cancer may help increase a patient’s immune response to tumors, according to recent findings from researchers at The Wistar Institute and their colleagues at University…
New Bioinformatics Tool Shows Promise for Matching Cancer Patients with Optimal Treatment Combinations
Recent OCRA-funded research has resulted in the creation of a new bioinformatics tool that holds potential for predicting the best treatment combinations for cancer patients…
OCRA Awards Two Ovarian Cancer Research Prizes
OCRA is pleased to announce the recipients of two research prizes, selected by members of our Scientific Advisory Committee for their notable contributions to the field of ovarian cancer research and commitment to future discoveries. Dr…
OCRA-Funded Research Points to Potential for Predicting Ovarian Cancer
New study findings not only reveal where the most common ovarian cancer subtype originates in certain patients, but also point to the future possibility of being able to predict who will get the disease…
OCRA Awards Nearly $6.5 Million in Ovarian Cancer Research Grants
More breakthroughs are on the horizon, as OCRA has awarded grants to 22 dedicated scientists at 15 prestigious medical institutions to enable future ovarian cancer discoveries…
Anne van Harten, PhD | Meet a Scientist
Dr. Anne van Harten, of the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award…
OCRA-Funded Research Reveals How Distinct Mutational Processes May Affect HGSOC Tumor Growth
OCRA grantees Ignacio Vázquez-García, PhD and Sohrab Shah, PhD, of Memorial Sloan Kettering Cancer Center, along with colleagues, have found that distinct mutational processes determine the different mechanisms by which certain…
The Overview: December 2021
This time of year always has us reflecting on what we’ve accomplished, what we hope to achieve in the future, and how we — with the support of the entire ovarian cancer community — can lean in even harder to our commitment…
OCRA-Funded Research Identifies New “Master” Drug Targets for Ovarian Cancer
An interdisciplinary group of researchers from around the country analyzed tumor samples from nearly 10,000 patients with 34 types of cancer to reveal unique genetic switches associated with each tumor type…
OCRA-Funded Study Identifies Antibiotic Found to Kill Tumor Cells Containing BRCA Mutations
A long-running study from Dana-Farber Cancer Institute, published in Nature Cancer and co-funded by OCRA, has discovered that the antibiotic novobiocin is capable of targeting and killing tumor cells in laboratory cell lines and tumor models with…
OCRA-Funded Research Provides a New Understanding of Ovarian Cancer Biology
OCRA-funded researcher Anil K. Sood, M.D., lead and senior author, and Sanghoon Lee, Ph.D…
OCRA-Funded Research Discoveries in 2020
It’s hard to believe 2020 is almost over, and what a year it’s been…